triple negative breast cancer (TNBC), HER2 positive breast cancer, and hormone receptor (HR) positive breast cancer, as a common targeted therapy effective in all the subtypes of breast cancer is not yet available. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.